AN2 Therapeutics, Inc. (ANTX)
NASDAQ: ANTX · Real-Time Price · USD
1.230
-0.060 (-4.65%)
Apr 25, 2025, 9:35 AM EDT - Market open
AN2 Therapeutics Employees
AN2 Therapeutics had 22 employees as of December 31, 2024. The number of employees decreased by 19 or -46.34% compared to the previous year.
Employees
22
Change (1Y)
-19
Growth (1Y)
-46.34%
Revenue / Employee
n/a
Profits / Employee
-$2,332,773
Market Cap
37.02M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 22 | -19 | -46.34% |
| Dec 31, 2023 | 41 | 5 | 13.89% |
| Dec 31, 2022 | 36 | 14 | 63.64% |
| Dec 31, 2021 | 22 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
ANTX News
- 4 weeks ago - AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights - Business Wire
- 7 weeks ago - AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conference - Business Wire
- 2 months ago - AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease - Business Wire
- 2 months ago - AN2 Therapeutics to Participate at Upcoming Investor Conferences - Business Wire
- 3 months ago - AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Business Wire
- 5 months ago - AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline - Business Wire
- 6 months ago - AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria - Business Wire
- 8 months ago - AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Business Wire